Aqilion AB has released promising results from new studies with molecules from the company’s lead series within the TAK1 program, demonstrating a strong disease-modifying effect in a well-established model of skin inflammation.
Casma Therapeutics Inc. has nominated its first development candidate, CSM-101, a first-in-class TRPML1 agonist. CSM-101 is being developed for the treatment of Gaucher’s disease patients with Parkinson’s disease, with the potential to expand into GBA-associated Parkinson’s disease and broader Parkinson’s disease populations.
BioWorld covers the Trump administration’s latest policy decisions and actions affecting the life sciences sector, as well as their impacts across the globe.
Kumquat Biosciences Inc. has described compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.
Evotec International GmbH has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, cryopyrin-associated periodic syndromes, hypertension, Alzheimer’s disease, rheumatoid arthritis, diabetes, multiple sclerosis and Parkinson’s disease.
Beijing Tide Pharmaceutical Co. Ltd. has identified protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer and myelofibrosis.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. have announced IND clearance by China’s National Medical Products Administration (NMPA) for NTB-003 (formerly BCG-009) for thyroid eye disease.
RSS
